KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $251.3 million.

  • Recursion Pharmaceuticals' Cash from Financing Activities rose 1426.79% to $251.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $400.2 million, marking a year-over-year increase of 6.96%. This contributed to the annual value of $304.1 million for FY2024, which is 117.02% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Cash from Financing Activities is $251.3 million, which was up 157.36% from $97.7 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Cash from Financing Activities high stood at $463.7 million for Q2 2021, and its period low was -$11.1 million during Q3 2021.
  • Over the past 3 years, Recursion Pharmaceuticals' median Cash from Financing Activities value was $40.5 million (recorded in 2025), while the average stood at $75.8 million.
  • Examining YoY changes over the last 5 years, Recursion Pharmaceuticals' Cash from Financing Activities showed a top increase of 121,288.74% in 2021 and a maximum decrease of 104.83% in 2021.
  • Recursion Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $3.8 million in 2021, then skyrocketed by 3,779.24% to $147.3 million in 2022, then slumped by 45.23% to $80.7 million in 2023, then plummeted by 86.81% to $10.6 million in 2024, then spiked by 1,426.79% to $251.3 million in 2025.
  • Its Cash from Financing Activities stands at $251.3 million for Q3 2025, versus $97.7 million for Q2 2025 and $40.5 million for Q1 2025.